Centre François Baclesse

Centre François Baclesse company information, Employees & Contact Information

Créé en 1923, le Centre François Baclesse de Caen exerce depuis près de 100 ans une triple mission en cancérologie: le soin, l’enseignement et la recherche. Il fait partie des 100 meilleurs hôpitaux du monde spécialisés en cancérologie (classement Newsweek 2020 et 2021). Il est le 1er centre français à obtenir la certification européenne EUSOMA pour son Institut Normand du Sein (INS). Ce label est attribué par la société européenne des spécialistes du cancer du sein (European Society of Breast cancer Specialists). Le Centre est certifié en A par la Haute Autorité de Santé (HAS), soit le niveau le plus élevé. Le Centre François Baclesse est l’un des 3 seuls centres en France à proposer l’innovation thérapeutique qu’est la protonthérapie. La protonthérapie est une forme de radiothérapie innovante permettant d’améliorer l’efficacité et de limiter la toxicité de certains traitements du cancer.

Company Details

Employees
576
Founded
-
Address
3 Avenue Général Harris, Caen,normandie 14000,france
Phone
33 2 31 45 50 50
Email
we****@****ncer.fr
Industry
Hospitals And Health Care
NAICS
Health Care and Social Assistance
Social Assistance
HQ
CAEN, Normandie
Looking for a particular Centre François Baclesse employee's phone or email?

Centre François Baclesse Questions

News

Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical response - Journal of Experimental & Clinical Cancer Research

Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical response Journal of Experimental & Clinical Cancer Research

Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial - Nature

Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial Nature

Case report: Musculoskeletal metastastic inflammatory myofibroblastic tumor (IMT) treated by sequential ALK-TKI with longterm response - Frontiers

Case report: Musculoskeletal metastastic inflammatory myofibroblastic tumor (IMT) treated by sequential ALK-TKI with longterm response Frontiers

Launch of the European programme DOSELIA: artificial intelligence in the service of paediatric radiotherapy - Gustave Roussy

Launch of the European programme DOSELIA: artificial intelligence in the service of paediatric radiotherapy Gustave Roussy

Obituary information for Charles Lee Johnson - Millard Family Chapels

Obituary information for Charles Lee Johnson Millard Family Chapels

Study IDs factors linked to risk for transfer from peritoneal dialysis to hemodialysis - Medical Xpress

Study IDs factors linked to risk for transfer from peritoneal dialysis to hemodialysis Medical Xpress

The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors - BMC Cancer

The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors BMC Cancer

Imputability of Adverse Events to Anticancer Drugs - The New England Journal of Medicine

Imputability of Adverse Events to Anticancer Drugs The New England Journal of Medicine

Cancer-related cognitive impairment in non-CNS cancer patients: Targeted review and future action plans in Europe - ScienceDirect.com

Cancer-related cognitive impairment in non-CNS cancer patients: Targeted review and future action plans in Europe ScienceDirect.com

Nomad Signs Editor Jessica Baclesse - Little Black Book | LBBOnline

Nomad Signs Editor Jessica Baclesse Little Black Book | LBBOnline

Meditation involving people with cancer, medical staff and witnesses: a pilot study exploring improvement in wellness and connectedness - BMJ Open

Meditation involving people with cancer, medical staff and witnesses: a pilot study exploring improvement in wellness and connectedness BMJ Open

Radioimmunotherapy for Brain Metastases: The Potential for Inflammation as a Target of Choice - Frontiers

Radioimmunotherapy for Brain Metastases: The Potential for Inflammation as a Target of Choice Frontiers

Potential of PSMA for breast cancer in nuclear medicine: digital quantitative immunohistochemical analysis and implications for a theranostic approach - BMC Cancer

Potential of PSMA for breast cancer in nuclear medicine: digital quantitative immunohistochemical analysis and implications for a theranostic approach BMC Cancer

Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes - Nature

Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes Nature

Ga generator use throughout its lifetime - Frontiers

Ga generator use throughout its lifetime Frontiers

The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer - BMC Cancer

The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer BMC Cancer

Summary report of the Standards, Options and Recommendations for malnutrition and nutritional assessment in patients with cancer (1999) - Nature

Summary report of the Standards, Options and Recommendations for malnutrition and nutritional assessment in patients with cancer (1999) Nature

Validation of an anti-α-Gal IgE fluoroenzyme-immunoassay for the screening of patients at risk of severe anaphylaxis to cetuximab - BMC Cancer

Validation of an anti-α-Gal IgE fluoroenzyme-immunoassay for the screening of patients at risk of severe anaphylaxis to cetuximab BMC Cancer

Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR) - BMC Cancer

Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR) BMC Cancer

Top Centre François Baclesse Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant